Previous investigators have demonstrated that animals which have become unresponsive (tolerant) to the analgesic effects of morphine due to repeated doses are also resistant to sedation caused by reserpine. Reserpine is known to exert its sedative effect pharmacologically by interfering with the storage mechanism of catecholamine and indoleamine neurotransmitters located in the synaptic vesicles of nerve cells. As a result of this interference the brain is largely depleted of these neurotransmitters.
In morphine tolerant animals, however, most of the catecholamines remain stored after treatment with reserpine. The mechanism of this resistance to reserpine has been investigated to determine if it may provide a clue to the as yet unknown mechanism of morphine tolerance.
The results demonstrate that morphine does not directly alter inhibition of the neurotransmitter storage mechanism by reserpine. Rather, morphine treatment restricts the amount of reserpine which reaches the brain, diminishing the effectiveness of the dose. This was true only for reserpine administered intraperitoneally, as done by previous investigators. Rats treated intravenously were as susceptible as control animals to depletion of catecholamines. It is concluded that reduced effectiveness of reserpine in depleting catecholamines in animals treated chronically with morphine is not related to tolerance by the central nervous system to morphine.
ABSTRACT
The mechanism of resistance to the catecholamine depleting effects of reserpine in morphine tolerant rats was examined. In vitro, morphine did not alter reserpine 3 inhibition of H-norepinephrine uptake by synaptic vesicles. Similarly, uptake by vesicles isolated from morphine tolerant animals was as susceptible to reserpine inhibition as that of corresponding preparations from saline treated controls. Consistent with earlier reports, intraperitoneally administered reserpine only partially reduced brain catecholamine levels in most rats treated chronically with morphine. However, reserpine injected intravenously depleted norepinephrine and dopamine in experimental animals to the same extent as controls treated by either route of administration. The amount of reserpine which actually reached the brain was estimated by intraperitoneal 3 injection of H-reserpine. Animals chronically treated with morphine and with only partially reduced norepinephrine concentrations exhibited tritium levels less than onehalf those of controls. It is concluded that an increased resistance to reserpine cannot be correlated with CNS tolerance to morphine. Rather, degradation or excretion of reserpine may be enhanced peripherally as a result of chronic morphine treatment.
I. INTRODUCTION
Development of tolerance to morphine in rats has been shown to be accompanied In vitro assay for norepinephrine uptake. Synaptic vesicles were isolated by a 13 modification of the methods described by Whittaker et al.
and De Robertis and 2 Rodriguez. Following resuspension of the crude synaptosomal pellet in water (2 ml/g 13 original tissue) as described by Whittaker et al., the homogenate was centrifuged at 20,000 x g for 20 minutes. The supernatant fraction was carefully pipetted off and further centrifuged at 110,000 x g for 50 minutes in a Beckman Model L2 centrifuge using a 50 rotor. The supernate was discarded and the pellet, containing partially purified synaptic vesicles, was gently resuspended by hand with a glass-Teflon homogenizer in 0.13 M K HPO buffer, pH 7.4. As a result of initial experiments, a volume of 5 ml was chosen for resuspension of a pellet obtained from two pooled rat brains (approximately 3. 5 g of tissue).
Uptake of norepinephrine was measured by a modification of the assay described 4 o by Euler and Lishajko.
The resuspended vesicles were preincubated at 23 C for 40 minutes, and 0. 5-ml aliquots (equivalent to approximately 0.35 g of brain) were added to 0. 5 ml of a reaction mixture. The 1-ml assay volume at pH 7.4 contained in -7 final concentration 2.5 mM MgCl , 2. 5 mM ATP, 0.13 M K HPO , and 6 x 10 M 3 H-dl-norepinephrine (340,000 dpm). Tubes containing the assay mix were immediately placed in a water bath shaker at 23 C. Uptake of H-norepinephrine was stopped by addition of 7 ml of ice-cold dl-norepinephrine solution (6 x 10 M). Samples were centrifuged at 110,000 x g for 45 minutes, supernatant fractions discarded, and the pellets washed once with 2 to 3 ml of water. The pellet was resuspended in 1 ml of water and counted in 10 ml of Aquasol (New England Nuclear) in a Nuclear-Chicago Mark II scintillation counter (efficiency of 45 percent). Blanks were prepared by mixing the reaction mix and vesicle suspension at 0 C, followed immediately by 7 ml of the cold norepinephrine solution. These blanks were indistinguishable from samples incubated at 0 C for several minutes. Statistics. The data were analyzed by the Student's "t" test.
in. RESULTS 3 Uptake of H-norepinephrine by synaptic vesicles in vitro. Initial experiments were made to determine linearity and energy requirements of the transport system.
3
-7 Uptake of H-norepinephrine (6 x 10 M) was linear for 3 minutes, the rate decreasing sharply thereafter ( Figure 1A ). Doubling the ATP concentrations from 2. 5 to 5 mM failed to increase the initial rate of accumulation ( Figure 1A) . However, the rate of uptake remained almost linear after 5 minutes, suggesting that loss of ATP can become a limiting factor on transport rate at longer incubation times. In the absence of added (Table I) . Vesicles isolated from either chronically or acutely morphine treated rats exhibited uptake rates similar to those of control animals. Likewise, 10 or 100 (iM morphine added in vitro had no significant effect on uptake.
To test the possibility of morphine-induced desensitization of synaptic vesicle 3 transport to reserpine, H-norepinephrine uptake was measured in the presence of varying concentrations of reserpine (Table II) . Vesicles from morphine tolerant animals appeared as susceptible to reserpine inhibition as those from controls. In the presence of both reserpine and morphine, vesicles from control rats showed an inhibition of uptake comparable to that of reserpine added alone (Table II) controls was estimated from a dose response curve. Rats made tolerant to 60 mg/kg morphine were given reserpine intraperitoneally 2 hours after the last morphine injection and euthanatized 4 hours later. As shown in Table III , levels of norepinephrine and dopamine were only partially diminished in the majority of morphine tolerant animals given reserpine intraperitoneally. The relatively normal behavior of these animals was in sharp contrast with the sedation of both controls and those morphine treated animals in which catecholamines were largely depleted.
The development of two populations (reserpine-resistant and reserpine-sensitive)
within the experimental group following intraperitoneal reserpine administration could not be explained by a variation in degree of tolerance as determined by the hot plate test. Reaction times were 11+5 seconds for morphine tolerant, reserpine-resistant;
13+8 seconds for morphine tolerant, reserpine-sensitive; and 5.5+2,2 seconds for the control.
The resistance to catecholamine depletion in morphine tolerant rats did not occur when reserpine was administered intravenously. Catecholamine levels in all experimental animals were not statistically different from those in either similarly treated or intraperitoneally injected controls (Table III) .
Levels of H-reserpine in the brain. To test the possibility that less intraperitoneally administered reserpine was reaching the brain in rats chronically treated 3 with morphine, levels of H-reserpine were measured in brains of control and experimental animals following intraperitoneal injection. As seen in Table IV , reserpine levels in morphine tolerant animals with only partially reduced norepinephrine concentrations were less than half those found in controls. 
IV. DISCUSSION
The results of this study strongly suggest that CNS tolerance to morphine is not involved in the observed resistance of amine stores to depletion by reserpine administered intraperitoneally. In earlier studies longer treatment regimens utilizing higher 7 8 doses of morphine were used to elicit this effect. ' However, reserpine was given intraperitoneally in every case. In our studies, most of the animals exhibiting tolerance to morphine also demonstrated a large degree of insensitivity to reserpineinduced depletion of amines provided the reserpine was administered intraperitoneally (Table III) . This phenomenon could be abolished by intravenous administration of the drug at a dose which was essentially equivalent (in terms of reduction in catecholamine levels) to the quantity given intraperitoneally (Table III) . This suggests that reserpine injected intraperitoneally may be preferentially metabolized or absorbed peripherally as a result of chronic morphine treatment, thus reducing its effectiveness in depleting brain catecholamines. That less reserpine reached the brain in tolerant animals, as compared to controls, was supported by the observation that lower levels of radioac-3 tivity were present in the brain following injection of H-reserpine.
A small number of tolerant animals were found to be sensitive to intraperitoneally administered reserpine. This could imply that in these animals an elimination mechanism of intraperitoneally injected reserpine may only be marginally induced by our 7 8 tolerance schedules. Studies ' which utilized larger doses and a more prolonged treatment showed all animals to be largely resistant to amine depletion by reserpine.
The in vitro assay permitted direct measurement of the effect of reserpine and morphine on norepinephrine transport by synaptic vesicles. The mechanism of depletion of catecholamine stores by reserpine involves inhibition of uptake and storage as demonstrated in vivo as well as in vitro with adrenergic nerve granules and hypothalamic vesicles.
Results of our studies are consistent with our in vivo findings.
There was both a lack of a direct protective effect by morphine toward reserpine inhibition as well as an unchanged sensitivity of the transport system toward reserpine after development of tolerance (Table II) .
Based on these findings, it is concluded that the acquired resistance to the amine depleting effects of intraperitoneally administered reserpine is not involved in the phenomena of CNS tolerance to morphine.
